Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.33 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.33 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29663911 | 1.00 | CASP3 (0.33) | CASP3RAB9AATMNPSR1SENP8 | |
| SCHEMBL10134245 | 0.77 | PDK2 (0.35) | CASP3RAB9AATMNPSR1SENP8 | |
| SCHEMBL29664192 | 0.77 | CSNK2A2 (0.40) | CASP3RAB9AATMNPSR1SENP8 | |
| SCHEMBL1962765 | 0.77 | CSNK2A2 (0.40) | CASP3RAB9AATMNPSR1SENP8 | |
| SCHEMBL28681359 | 0.74 | PDK2 (0.39) | CASP3RAB9AATMNPSR1SENP8 | |
| SCHEMBL29664262 | 0.73 | PDK2 (0.36) | CASP3RAB9AATMNPSR1SENP8 | |
| SCHEMBL1959954 | 0.73 | PDK2 (0.36) | CASP3RAB9AATMNPSR1SENP8 | |
| SCHEMBL16713268 | 0.72 | CNR2 (0.37) | RAB9AL3MBTL1CA1CA2CA7 | |
| SCHEMBL3141421 | 0.71 | PDK2 (0.36) | — | |
| SCHEMBL2630542 | 0.71 | RAB9A (0.40) | CASP3RAB9AATMNPSR1SENP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107253943-B | Photochromic compounds and compositions | 光学转变公司 | 2022-05-17 | — | — | CN | disclosed |
| EP-2651912-B1 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | TRANSITIONS OPTICAL INC (US) | 2018-10-03 | — | — | EP | disclosed |
| US-9034219-B2 | Photochromic compounds and compositions | TRANSITIONS OPTICAL, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-20120156521-A1 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | TRANSITIONS OPTICAL, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120156521-A1 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | CRY2, CRY1, PPOX | CASP3 1461/4885RAB9A 2888/4885ATM 1017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.